13 completed, 7 unknown, 4 not yet recruiting, 3 terminated. 32 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 32 | Completed 13, Unknown 7, Not yet recruiting 4, Terminated 3, Recruiting 2, Withdrawn 2, Active not recruiting 1 |
Follow Nevi and Melanomas: new trials by email Literature Review of Nevi and Melanomas trials Research Report on Nevi and Melanomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus) - Melanoma, Acral Melanoma | Phase 4 | Not yet recruiting | Peking University Cancer Hospital & Institute | 76 | 2026-10-01 | 2026-10-02 |
| Impact of Dysport on PMFF Donor Scar Abobotulinumtoxin-A, Control- Saline injection - Skin Cancer Excision Site, Basal Cell Carcinoma | Phase 4 | Not yet recruiting | Vanderbilt University Medical Center | 50 | 2026-09-14 | 2026-08-26 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib Encorafenib & Binimetinib Treatment - Melanoma BRAF V600E/K Mutated | Phase 4 | Withdrawn | SRH Wald-Klinikum Gera GmbH | 2025-08-01 | 2026-04-21 | |
| Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis Atorvastatin, Placebo - Atherosclerosis, Melanoma | Phase 4 | Not yet recruiting | Erasmus Medical Center | 140 | 2025-02-01 | 2025-01-22 |
| Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG MSOT - Melanoma, Stage I, Melanoma, Stage II | Phase 4 | Unknown | University Medical Center Groningen | 10 | 2022-09-01 | 2022-07-20 |
| Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response Nivolumab - Melanoma | Phase 4 | Unknown | Erasmus Medical Center | 34 | 2022-01-05 | 2024-04-22 |
| A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS) Crysvita (burosumab-twza) Treatment - Epidermal Nevus Syndrome | Phase 4 | Completed | University of Alabama at Birmingham | 1 | 2020-07-31 | 2022-10-07 |
| Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer Lymphoseek, Nanocoll - Head Cancer, Neck Cancer | Phase 4 | Unknown | Anna Cruceta | 30 | 2020-03-01 | 2020-02-20 |
| Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies immune-checkpoint inhibitors therapies - Advanced or Metastatic Melanoma, Advanced or Metastatic NSCLC | Phase 4 | Terminated | Institut Paoli-Calmettes | 40 | 2019-10-16 | 2026-01-22 |
| Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Melanoma | Phase 4 | Completed | Merck Sharp & Dohme LLC | 150 | 2019-01-31 | 2025-08-29 |
| Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Nivolumab, MRI, BLOOD SAMPLES - Melanoma, Non-small Cell | Phase 4 | Unknown | Assistance Publique Hopitaux De Marseille | 50 | 2018-04-09 | 2023-04-21 |
| Dabrafenib and/or Trametinib Rollover Study dabrafenib, trametinib - Melanoma, Non Small Cell Lung Cancer | Phase 4 | Recruiting | Novartis Pharmaceuticals | 100 | 2018-01-26 | 2026-10-22 |
| Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study Propofol, isoflurane, sevoflurane or desflurane - Cancer, Breast, Cancer Colorectal | Phase 4 | Completed | Peter MacCallum Cancer Centre, Australia | 169 | 2017-08-27 | 2022-06-09 |
| Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream 5-aminolevulinic acid nanoemulsion - Lentigo Maligna | Phase 4 | Completed | Joint Authority for Päijät-Häme Social and Health Care | 10 | 2016-02-01 | 2018-05-30 |
| Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma GM-CSF, Standard of Care - Melanoma | Phase 4 | Completed | Mayo Clinic | 8 | 2015-05-01 | 2020-02-10 |
| Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies blood sampling, Nivolumab - Metastatic Melanoma | Phase 4 | Completed | Hospices Civils de Lyon | 32 | 2015-04-23 | 2025-09-15 |
| TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Triamcinolone Acetonide, Transpupillary thermotherapy - Exudative Retinal Detachment, Uveal Melanoma | Phase 4 | Unknown | Charite University, Berlin, Germany | 50 | 2015-01-01 | 2017-02-08 |
| A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Blood sampling for Pre-existing immunity, Ipilimumab - Malignant Melanoma | Phase 4 | Active not recruiting | Oslo University Hospital | 150 | 2014-01-01 | 2023-03-24 |
Showing 20 of 32. Sign in to see all of them.
Melanoma (27) · Lung Neoplasms (5) · Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (3) · Neoplasms (3) · Skin Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2) · Hutchinson's Melanotic Freckle (2) · Prostatic Neoplasms (2) · Uveal Melanoma (2) · Acromegaly (1)
Neoplasms by Histologic Type (32) · Neoplasms, Germ Cell and Embryonal (31) · Neoplasms, Nerve Tissue (31) · Neuroectodermal Tumors (31) · Neuroendocrine Tumors (30) · Neoplasms (29) · Neoplasms by Site (29) · Skin Diseases (27) · Skin and Connective Tissue Diseases (27) · Skin Neoplasms (24) · Lung Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Respiratory Tract Diseases (7)
Nivolumab (4) · Blood Specimen Collection (3) · aldesleukin (3) · Ipilimumab (2) · Vemurafenib (2) · Aminolevulinic Acid (1) · Atorvastatin (1) · BF-200 ALA (1) · Botulinum Toxins, Type A (1) · Cabergoline (1) · Cisplatin (1) · Craniotomy (1) · Dacarbazine (1) · Desflurane (1) · Etanercept (1)
Clinigen, Inc. (2) · Erasmus Medical Center (2) · Novartis Pharmaceuticals (2) · University of Alabama at Birmingham (2) · Anna Cruceta (1) · Assistance Publique Hopitaux De Marseille (1) · Bristol-Myers Squibb (1) · Charite University, Berlin, Germany (1) · Dartmouth-Hitchcock Medical Center (1) · Dermatologic Cooperative Oncology Group (1) · Hoffmann-La Roche (1) · Hospices Civils de Lyon (1) · Institut Paoli-Calmettes (1) · Jerry Marsden (1) · Joint Authority for Päijät-Häme Social and Health Care (1)
United States (13) · France (5) · Germany (4) · Netherlands (4) · India (3) · Spain (3) · Argentina (2) · Canada (2) · Hungary (2) · Japan (2) · Russia (2) · Thailand (2) · Australia (1) · Austria (1) · Belgium (1)
Axel Hauschild, MD (1) · Boni E Elewski, MD (1) · Carol L Shields, MD (1) · Erna Snellman, Professor (1) · Henk P. Giele, MBBS FRACS (1) · Hussein Abdul-Latif, MD (1) · Ira Seibel, MD (1) · James Jakub, MD (1) · James Lowder, MD (1) · Jens Ulrich, MD (1)
PMID 21456091, PMID 30053905, PMID 30821848, PMID 35230185, PMID 35899095, PMID 36116420, PMID 38939518
2017 (1), 2018 (1), 2019 (1), 2023 (1)